The BCL-2-specific BH3-mimetic drug Venetoclax is used for the treatment of patients with CLL and AML, and inhibitors of MCL-1 or BCL-XL have shown efficacy in pre-clinical models but are less advanced clinically [16]. This evidence concerns the gene BCL2 and acute myeloid leukemia.